&nbsp;

CancerInFirstNationsPeopleInOntario.pdf

Apr 2018

Document

CCO Participant Info Form-FR

May 2018

Regimen

CHOP

Cancer Type:

Hematologic,

Lymphoma - T-cell

Intent: Curative

Funding:

ODB - General Benefit

prednisone

Drugs Used:

Quick Link(s):

Regimen Monograph

May 2018

Regimen

CRBPPEME+BEVA

Cancer Type:

Lung,

Mesothelioma (Pleural)

Intent: Palliative

Drugs Used:

pemetrexed,

CARBOplatin,

bevacizumab (Unfunded)

Quick Link(s):

Regimen Monograph

Jun 2021

Regimen

CISPPEME(RT)

Cancer Type:

Lung,

Non-Small Cell

Intent: Curative, Adjuvant

Drugs Used:

pemetrexed,

CISplatin

Quick Link(s):

Regimen Monograph

Jan 2019

Regimen

CISPPEME+PEMB

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab - In Combination with Platinum and Pemetrexed for First Line Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Drugs Used:

Quick Link(s):

Regimen Monograph

Aug 2022

Regimen

CRBPPEME+PEMB

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab - In Combination with Platinum and Pemetrexed for First Line Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Drugs Used:

Quick Link(s):

Regimen Monograph

Aug 2022

Document

ColonCancerCheck Primary Care Provider Registration - Patient Attachment

Aug 2018

Document

2018 CSRT CoP Annual Report

Aug 2018

Regimen

CRBPPACL

Cancer Type:

Endocrine,

Thyroid

Intent: Palliative

Drugs Used:

PACLitaxel,

CARBOplatin

Quick Link(s):

Regimen Monograph

May 2019

Regimen

CISPGEMC

Cancer Type:

Genitourinary,

Bladder / Urothelial

Intent: Neoadjuvant, Adjuvant

Drugs Used:

gemcitabine,

CISplatin

Quick Link(s):

Regimen Monograph

May 2019

Regimen

CISPGEMC(W)

Cancer Type:

Genitourinary,

Bladder / Urothelial

Intent: Neoadjuvant, Adjuvant

Drugs Used:

CISplatin,

gemcitabine